Advertisement
Eli Lilly
Subscribe to Eli Lilly

The Lead

Lilly Second Quarter Profit Falls 39%

July 24, 2014 7:31 am | by The Associated Press | News | Comments

Eli Lilly and Co. (LLY) on Thursday reported profit that declined by 39 percent in its second quarter, and beat analysts' expectations. The Indianapolis-based company said earnings declined to $733.5 million, or 68 cents per share, from $1.21 billion, or $1.11 per share, in the same quarter a year earlier.

Anthera Pharmaceuticals Acquires Sollpur for Exocrine Pancreatic Insufficiency From Eli Lilly

July 15, 2014 9:04 am | News | Comments

Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of...

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

June 27, 2014 8:20 am | News | Comments

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion...

Analyst: Sanofi Facing Triple Threat from Eli Lilly for Diabetes Treatment Market Space

June 25, 2014 8:13 am | News | Comments

The imminent patent expiration of Sanofi’s Lantus has opened the door for Eli Lilly to increase...

View Sample

FREE Email Newsletter

Lilly Declares Q3 2014 Dividend

June 16, 2014 3:02 pm | by Lilly | News | Comments

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2014 of $0.49 per share on outstanding common stock.                                        

Lilly Announces Results Of Phase III Hepatocellular Carcinoma Trial

June 11, 2014 8:16 am | News | Comments

Eli Lilly and Company today announced that the Phase III REACH trial of CYRAMZA (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant.

Healthy Seniors Tested In Bid to Block Alzheimer's

June 10, 2014 8:44 am | by LAURAN NEERGAARD, AP Medical Writer | News | Comments

In one of the most ambitious attempts yet to thwart Alzheimer's disease, a major study got underway Monday to see if an experimental drug can protect healthy seniors whose brains harbor silent signs that they're at risk.     

Advertisement

Lilly Announces Increased Access to Clinical Trials Data for Qualified Researchers

June 2, 2014 8:15 am | News | Comments

Eli Lilly and Company today announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This website, which houses data from several clinical trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

New Drugs May Make a Dent in Lung, Ovarian Cancer

May 31, 2014 10:55 am | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

For the first time in a decade, an experimental drug has extended the life of patients with advanced lung cancer who relapsed after standard chemotherapy. But the benefit in the study was so small — six extra weeks, on average — that it is raising fresh questions about the value of some costly...

Sanofi and Lilly Announce Licensing Agreement for Cialis OTC

May 28, 2014 8:39 am | News | Comments

Sanofi and Eli Lilly and Company today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).

European Commission Approves Jardiance Tablets for Use in Adults in Europe

May 23, 2014 8:02 am | News | Comments

The European Commission granted marketing authorization for Jardiance (empagliflozin) tablets, a sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of type 2 diabetes mellitus (T2D) to improve glycemic control in adults in Europe, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced.

Lilly to Appeal $450M Brazil Court Ruling in Labor Case

May 12, 2014 8:36 am | News | Comments

Eli Lilly and Company has announced that the 2nd Circuit of the Labor Court of Paulinia in the state of Sao Paulo, Brazil, has ruled against the company's local subsidiary, Eli Lilly do Brasil, in a labor case alleging some employees were exposed to hazardous materials in a manufacturing facility operated by the company between 1977 and 2003.

Advertisement

Deal Flurry Shows Drug Makers’ Move to Specialization

April 24, 2014 8:58 am | Videos | Comments

The recent flurry of drug deals shows how the global pharmaceutical industry is reversing course, as companies narrow their focus after decades of diversifying their drug portfolios.            

Eli Lilly First Quarter Profit Plunges

April 24, 2014 8:11 am | News | Comments

Eli Lilly's first-quarter earnings plunged 53 percent after the expiration of a key patent protecting its top-selling antidepressant cut into the drugmaker's revenue.              

Investor Pressure Pushing Pharmaceutical M&A Deals

April 22, 2014 7:31 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.

Three More Charged in $80M Eli Lilly Heist in Connecticut

April 22, 2014 6:29 pm | by John Christoffersen - Associated Press - Associated Press | News | Comments

Federal authorities have charged three more Florida men in the theft of about $80 million in prescription drugs from an Eli Lilly warehouse in Connecticut. The 2010 heist is believed to be the largest theft in Connecticut history, and included thousands of boxes of Zyprexa, Cymbalta, Prozac,...

Novartis and Glaxo Deal Reshapes Pharma Industry

April 22, 2014 8:58 am | Videos | Comments

Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. The WSJ explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.

Advertisement

FDA Approves Cyramza for Stomach Cancer

April 22, 2014 8:05 am | News | Comments

The FDA has approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the region where the esophagus joins the stomach.       

Novartis, GSK, Lilly in Multibillion-Dollar Deals

April 22, 2014 4:28 am | by John Heilprin - Associated Press - Associated Press | News | Comments

Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally.

US Court Backs Patent for Eli Lilly's Alimta

April 1, 2014 8:52 am | News | Comments

A federal court has upheld the patent that protects Eli Lilly's lung cancer treatment from generic competition until 2022.                       

Facility Concerns Kill Lilly-Boehringer Diabetes Drug

March 5, 2014 11:05 am | News | Comments

Eli Lilly and Boehringer-Ingelheim said  that the Food and Drug Administration didn't approve their diabetes treatment empagliflozin because of concerns about a facility where the drug will be made.        

Generic Evista® Tablets 60 mg Approved in the United States

March 4, 2014 9:42 am | News | Comments

Teva Pharmaceutical has announced the approval of the generic equivalent to Evista® (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.    

Lilly Diabetes Drug Meets Late-Stage Goal

February 25, 2014 11:09 am | News | Comments

Lilly said that a once-weekly, 1.5-milligram dose of dulaglutide was not inferior to a daily, 1.8 milligram dose of Novo Nordisk's Victoza in a study of nearly 600 patients who were already taking metformin, an older diabetes treatment.   

Group Wants Heart Attack Warning on Testosterone

February 25, 2014 8:25 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

A consumer advocacy group is calling on the Food and Drug Administration to add a bold warning label to popular testosterone drugs for men in light of growing evidence that the hormone treatments can increase the risk of heart attack.   

Lilly Buys Animal Health Business, Lowers Forecast

February 24, 2014 11:17 am | by The Associated Press | News | Comments

Eli Lilly is buying a privately held, poultry vaccine maker to strengthen its Elanco animal health subsidiary. No terms were released, but Lilly said Monday that its 2014 earnings forecast will be trimmed due to acquisition costs.    

Partners in New NIH-Industry Project to Find Meds

February 4, 2014 1:43 pm | by The Associated Press | News | Comments

Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.

Eli Lilly Issues Statement in Response to Sanofi U.S. Lawsuit

January 31, 2014 12:06 pm | News | Comments

Eli Lilly and Company has provided the following statement regarding a lawsuit filed by Sanofi in the United States District Court for the District of Delaware alleging patent infringement with respect to LY2963016, a new insulin glargine product for which Lilly is currently seeking approval from the FDA.

Lilly Fourth Quarter Profit Falls 12%

January 30, 2014 8:01 am | News | Comments

Eli Lilly and Co.'s fourth-quarter earnings dropped 12 percent as the drugmaker lost U.S. patent protection for its top-selling product, and cheaper generic competition started to eat away at results.        

Eli Lilly Forecasts Profit, Revenue Drop in 2014

January 7, 2014 1:31 pm | by TOM MURPHY, AP Business Writer | News | Comments

Eli Lilly and Co. expects a sharp drop in both earnings and revenue in the new year, as the drug developer deals with the loss of patents protecting two more key drugs from cheaper generic competition. The Indianapolis company forecast on Tuesday earnings of between $2.77 and $2.85 per share in 2014, a decrease of more than 30 percent from the range of $4.10 to $4.15 per share that it expects to report for 2013.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading